microRNAs as peripheral blood biomarkers of cardiovascular disease

Stefano, Valeria Di; Zaccagnini, Germana; Capogrossi, Maurizio C.; Martelli, Fabio

doi:10.1016/j.vph.2011.08.001

Cited by 67 publications

(54 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A new frontier has been opened by the recent discovery that miRNAs are present in the bloodstream and in other bodily fluids, in a remarkably stable form (36,135). Because of their stability and their tissue-and disease-specific expression and the possibility to measure them with high specificity and sensitivity, miRNAs are emerging diagnostic biomarkers.…”

Section: Diagnostic/prognostic Perspectivesmentioning

confidence: 99%

“…Indeed, mounting evidence accumulating in the last few years shows that miRNAs are present not only in tissues, but also in various biological fluids including blood, urine, and saliva (36,135). Remarkably, miRNAs circulate in the peripheral blood in a highly stable, cell-free form that is protected from endogenous RNase activity and can be detected in both plasma and serum.…”

mentioning

confidence: 99%

See 1 more Smart Citation

HypoxamiR Regulation and Function in Ischemic Cardiovascular Diseases

Greco

Gaetano

Martelli

2014

Antioxidants & Redox Signaling

Self Cite

View full text Add to dashboard Cite

Significance: MicroRNAs (miRNAs) are deregulated and play a causal role in numerous cardiovascular diseases, including myocardial infarction, coronary artery disease, hypertension, heart failure, stroke, peripheral artery disease, kidney ischemia-reperfusion. Recent Advances: One crucial component of ischemic cardiovascular diseases is represented by hypoxia. Indeed, hypoxia is a powerful stimulus regulating the expression of a specific subset of miRNAs, named hypoxia-induced miRNAs (hypoxamiR). These miRNAs are fundamental regulators of the cell responses to decreased oxygen tension. Certain hypoxamiRs seem to have a particularly pervasive role, such as miR-210 that is virtually induced in all ischemic diseases tested so far. However, its specific function may change according to the physiopathological context. Critical Issues: The discovery of HypoxamiR dates back 6 years. Thus, despite a rapid growth in knowledge and attention, a deeper insight of the molecular mechanisms underpinning hypoxamiR regulation and function is needed. Future Directions: An extended understanding of the function of hypoxamiR in gene regulatory networks associated with cardiovascular diseases will allow the identification of novel molecular mechanisms of disease and indicate the development of innovative therapeutic approaches.

show abstract

Section: Diagnostic/prognostic Perspectivesmentioning

confidence: 99%

mentioning

confidence: 99%

HypoxamiR Regulation and Function in Ischemic Cardiovascular Diseases

Greco

Gaetano

Martelli

2014

Antioxidants & Redox Signaling

Self Cite

View full text Add to dashboard Cite

show abstract

“…[20][21][22][23][24] Since miRNAs can be readily detected in various body fluids, 25,26 they have been advanced as useful biomarkers for the diagnosis and characterization of systemic diseases, 27 including type 2 diabetes mellitus, 28 hypertension, 29 obesity, 30 and cardiovascular disease. 31 Peripheral blood miRNAs, including miRNAs expressed by peripheral blood mononuclear cells, as well as extracellular/circulating miRNAs may, thus, provide an easy and rapid screening approach in clinical populations 32 and add to the accuracy of current CVD risk stratification criteria.…”

mentioning

confidence: 99%

Circulating microRNAs as Potential Biomarkers of Endothelial Dysfunction in Obese Children

Khalyfa

Kheirandish‐Gozal

Bhattacharjee

et al. 2016

Chest

View full text Add to dashboard Cite

BACKGROUND: Cardiovascular disease (CVD) is a complex disease with multifactorial etiology. The presence of endothelial dysfunction constitutes an early risk factor for CVD in children. Circulating microRNAs (miRNAs) are small noncoding RNAs that regulate gene expression and represent a novel class of biomarkers and therapeutic targets; therefore, we examined whether the presence of endothelial dysfunction is associated with differential expression of plasma miRNAs in otherwise healthy children.

show abstract

“…The differences in miRNAs expression have been implicated in disease onset and/or progression with potential of diagnostic and/or prognostic biomarkers (2). More than 200 miRNAs were found in the heart with the biological role as cellular regulators involved in metabolic processes, proliferation, growth of the endothelial cells and myocytes, angiogenesis, contractility and cardiac rhythm (3). MiRNA expression varies with the progression of cardiovascular diseases including acute ischemia, myocardial infarction, cardiac hypertrophy, and cardiac failure (4,5).…”

Section: Introductionmentioning

confidence: 99%

MicroRNAs in pathophysiology of acute myocardial infarction and cardiogenic shock

Mp¹,

Lipková²,

J³

et al. 2018

BLL

View full text Add to dashboard Cite

AIM: Levels of circulating miRNA are considered to be potential biomarkers of acute myocardial infarction and disease progression. METHODS: In this study, the expression levels of circulating miRNA-1, miRNA-133 and miRNA-124a were investigated in a group of patients with acute myocardial infarction (STEMI) and cardiogenic shock (CS) compared to controls. RESULTS: During the hospitalization period, miRNA-133 showed a signifi cant up-regulation in the serum of STEMI and CS patients compared to controls, while the expression of miRNA-1 was signifi cantly different only in CS. The expression of miRNA-124 was signifi cantly higher in STEMI and CS. Furthermore, miRNA-1 expression was related to the level of circulating glucose in patients with STEMI. We also found a negative correlation between miRNA-133 and MMP-9 levels. MiRNA-124 expression was signifi cantly related to the level of soluble ST2; the marker correlated to cardiac damage. CONCLUSION: All selected miRNAs are potential markers of cardiac injury in cardiogenic shock, whereas miRNA-124a and -133 are markers of injury in STEMI. MiRNA-1 expression is related to circulating glucose in STEMI. None of miRNAs could be correlated to the extent of injury, progress of the disease, or prognosis of patient outcome. Therefore, the levels of circulating miRNA have no potential for becoming a biomarker of myocardial damage and as such would bring no further benefi t compared to current markers (Tab. 4, Fig. 1, Ref. 47). Text in PDF www.elis.sk.

show abstract

microRNAs as peripheral blood biomarkers of cardiovascular disease

Cited by 67 publications

References 82 publications

HypoxamiR Regulation and Function in Ischemic Cardiovascular Diseases

HypoxamiR Regulation and Function in Ischemic Cardiovascular Diseases

Circulating microRNAs as Potential Biomarkers of Endothelial Dysfunction in Obese Children

MicroRNAs in pathophysiology of acute myocardial infarction and cardiogenic shock

Contact Info

Product

Resources

About